REVIEW

Conjunctivitis in patients with atopic dermatitis treated with dupilumab

Sandra Ferreira MD, Tiago Torres MD, PhD

Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal

Abstract

Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL-13 are key cytokines in the immunopathogenesis of AD. New emerging agents include dupilumab, a fully human monoclonal antibody directed against the IL-4 receptor α subunit that blocks both IL-4 and IL-13 signaling and has shown significant efficacy in patients with moderate-to-severe AD. Dupilumab is approved for the treatment of moderate-to-severe AD, moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma, and chronic rhinosinusitis with nasal polyps. Data from phase phase 2 and 3 studies have revealed that dupilumab generally has a low rate of adverse events, although an increased incidence of mild-to-moderate conjunctivitis has been reported for dupilumab compared with placebo.

The present paper reviews the data of dupilumab-associated conjunctivitis and risk factors in adults with moderate-to-severe AD and other atopic diseases in dupilumab clinical trials and addresses the characteristics and treatment options available for this clinically highly relevant condition. Additionally, it presents data from ten studies in the real-life setting with dupilumab. Dupilumab-associated conjunctivitis incidence is higher in AD, although most cases are mild-to-moderate and have good response to topical treatment, with no need to suspend dupilumab therapy.

Keywords: atopic dermatitis, atopic eczema, conjunctivitis, dupilumab.

Citation

Ferreira F, Torres T. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs in Context 2020; 9: 2020-2-3. DOI: 10.7573/dic.2020-2-3

Background

Atopic dermatitis (AD) is a common, chronic, inflammatory skin condition that affects up to 25% of children and 5% of adults worldwide. Patients with AD have an increased risk of developing ocular disorders, such as keratoconus, cataract, glaucoma, and blepharitis, as well as allergic, atopic, and infectious (kerato) conjunctivitis.

Topical treatment is usually sufficient to control the disease in the majority of patients, although systemic treatment may be required in some patients due to the severity of the skin disease. Several biologic therapies are currently being developed and evaluated in clinical trials. To date, dupilumab has been the first targeted biologic agent approved in the United States and the European Union for the treatment of moderate-to-severe AD in adults.

Dupilumab is a fully human monoclonal antibody directed against the interleukin 4 receptor α (IL-4Ra) subunit that blocks both IL-4 and IL-13 signaling, improving both objective signs and subjective symptoms of the disease. Dupilumab has been shown to be effective and safe in asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis (EoE), suggesting that IL-4 and IL-13 are pivotal drivers of numerous type 2 inflammatory diseases. Dupilumab has demonstrated rapid improvement in patients with moderate-to-severe AD and a favorable safety profile across all studies; however, an increased incidence of conjunctivitis has been observed in patients receiving dupilumab compared with those treated with placebo. Nevertheless, most patients with dupilumab-associated conjunctivitis (DAC) experienced mild disease, while moderate events were less frequent.

Although the incidence of ophthalmic complications seems to increase with the disease severity at baseline and in association with other atopic comorbidities, such as asthma and allergic rhinitis, and previous conjunctivitis history, risk factors for the development of DAC remain unclear.

Methods

A narrative review of the literature was written after retrieving relevant articles from the PubMed database (up until January...
REVIEW – Conjunctivitis associated with dupilumab

Incidence of conjunctivitis in dupilumab clinical trials

A greater incidence of conjunctivitis was noticed among dupilumab treatment groups compared with placebo in one phase 2b and four phase 3 AD clinical trials – SOLO1, SOLO2, CHRONOS, and CAFE (Table 1).

In the monotherapy combined group (phase 2b, SOLO 1, and SOLO 2; either dupilumab 300 mg weekly [qw], dupilumab 300 mg every 2 weeks [q2w], or placebo qw), 88 patients in the dupilumab group developed conjunctivitis after 16 weeks of treatment with an incidence rate of 8.4% (n=88/1047) versus 2.3% (n=12/517) in the placebo group.

In the CHRONOS study, the incidence rates of DAC for dupilumab associated with topical corticosteroid (TCS) compared with placebo in association with TCS over the 52-week trial length were 17.9% (n=48/217) and 7.9% (n=25/315), respectively.

In the SOLO-CONTINUE trial, patients who were good responders to dupilumab in both SOLO trials were re-randomized to more 36 weeks of treatment at their original dosage or longer interval schemes (every 4 weeks [q4w] or every 8 weeks [q8w]) or placebo. Contrary to the other AD studies, no noticeable disparity in conjunctivitis incidence rate was detected between the dupilumab and placebo groups (n=16/338, 4.7%, versus n=4/82, 4.9%, respectively). Additionally, in the CHRONOS and SOLO-CONTINUE studies, both dupilumab-dosing schemes presented with identical incidence rates of DAC in the monotherapy group.

The CAFÉ trial reported the highest conjunctivitis rates, with incidence rates of 22.1% (n=48/217) versus 11.1% (n=12/108) for dupilumab associated with TCS versus placebo plus TCS over the 16-week trial length, respectively.

While conjunctivitis was a significant adverse event (AE) occurring in patients with AD treated with dupilumab, there was no significant increased risk of DAC in all asthma trials (n=30/2007, 1.5% for dupilumab versus n=19/929, 2.0% for placebo) (Table 2).

In the chronic rhinosinusitis with nasal polyposis clinical trial, only one patient in the placebo group developed conjunctivitis (3.3%), while none occurred within dupilumab-treated group (Table 2).

Also, in the EoE study, there was no conjunctivitis reported.

LIBERTY AD ADOL was a randomized, double-blind, parallel-group, phase 3 clinical trial conducted at 45 US and Canadian centers and included 251 adolescents (aged ≥12 to <18 years) with moderate-to-severe AD inadequately controlled by topical therapies or for whom topical treatment was not recommended. Patients were randomized (1:1:1) to receive treatment with subcutaneous dupilumab q2w (200 mg, n=43; baseline weight < 60 kg; or 300 mg, n=39; baseline weight ≥ 60 kg) or q4w (300 mg, n=84), or placebo q2w (n=85) during 16 weeks. DAC incidence was higher within dupilumab groups when compared with placebo (q2w, n=8/82, 9.8%; q4w, n=9/84, 10.8%; placebo, n=4/85, 4.7%) (Table 3). These results are consistent with those from dupilumab adult trials in AD.

Conjunctivitis characteristics in dupilumab clinical trials

Conjunctivitis events were mainly mild to moderate, and almost all recuperated with topical eye drops until the termination of the trial period. Treatment options more frequently prescribed were eye drops of corticosteroids, antibiotics, antihistamines, or mast cell stabilizers. Severe cases were only reported in less than 1% of patients. In the CHRONOS study, one patient receiving dupilumab 300 mg qw plus TCS was suspended due to conjunctivitis, namely keratoconjunctivitis in one eye. Also, in the monotherapy group, another patient receiving dupilumab 300 mg qw interrupted repeatedly due to conjunctivitis.

Differences in new conjunctivitis events between placebo and dupilumab were observed after week 2 in the monotherapy group, after weeks 6–8 in CHRONOS, and after weeks 4–8 in CAFÉ. While new DAC events occurred at a steady rate throughout 16 weeks in the monotherapy group and CAFÉ study, in the CHRONOS trial, new cases seemed to level off around weeks 20–24 and were unusual after week 44. In these AD studies, mean time to first occurrence was identical among dupilumab-dosing schemes.

Independently of the treatment group, DAC occurred more frequently in patients who had severe AD at baseline, a prior history of conjunctivitis, and low serum levels of dupilumab. Additionally, higher baseline Thymus and activation-regulated chemokine (TARC) and immunoglobulin E (IgE) serum levels and higher baseline circulating eosinophil counts were also observed in patients with conjunctivitis in both groups.

Dupilumab efficacy seems to be associated with conjunctivitis incidence. In the monotherapy group, individuals who accomplished high-level effectiveness results, namely an Investigator’s Global Assessment (IGA) of 0 or 1 (IGA 0/1) or 75% improvement from baseline in the Eczema Area and Severity Index (EASI-75), had less susceptibility to develop DAC than those who did not achieve those results. However, this trend was merely noted in the dupilumab q2w and placebo groups, in both CHRONOS and CAFÉ trials.
## Table 1. Incidence of conjunctivitis in atopic dermatitis dupilumab trials* – phase 2b, SOLO 1, SOLO 2, CHRONOS, CAFÉ, and SOLO-CONTINUE

| Patients with at least 1 event, n (%) | Monotherapy Group** | CHRONOS | CAFÉ | SOLO-CONTINUE |
|--------------------------------------|---------------------|---------|------|---------------|
|                                      |                     | Placebo + TCS combined (n=107) | Dupilumab 300 mg qw + TCS (n=110) | Dupilumab 300 mg q2w + TCS (n=107) |
| Dupilumab (combined) (n=1047)        |                     | (n=217) | (n=110) | (n=107) |
| Dupilumab 300 mg qw (n=518)          |                     | 25 (7.9%) | 30 (28.0%) | 18 (16.4%) |
| Dupilumab 300 mg q2w (n=529)         |                     | 48 (22.1%) | 48 (22.1%) | 30 (28.0%) |
| Placebo (n=517)                      |                     | 12 (2.3%) | 18 (16.4%) | 12 (11.1%) |
| Conjunctivitis†§                     | 88 (8.4%)           | 40 (7.7%) | 48 (9.1%) | 12 (2.3%) |

*These results are expressed in number of patients (percent).

**Include data pooled for phase 2b trial and phase 3 trials SOLO 1 and SOLO 2.

†MEDRA PT.

§Cluster of preferred terms includes conjunctivitis of unspecified cause, allergic, bacterial and viral conjunctivitis, and atopic keratoconjunctivitis.

MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; qw, once weekly; q2w, every 2 weeks; q4W, every 4 weeks; q8w, every 8 weeks; TCS, topical corticosteroid.

## Table 2. Incidence of conjunctivitis in other type 2 disorders dupilumab trials* – phase 2b (DRI12544); LIBERTY ASTHMA QUEST; LIBERTY ASTHMA VENTURE; and chronic rhinosinusitis with nasal polyposis (ACT12340)

| Patients with at least 1 event, n (%) | Phase IIb DRI12544 | LIBERTY ASTHMA QUEST | LIBERTY ASTHMA VENTURE | ACT12340 |
|--------------------------------------|--------------------|-----------------------|------------------------|----------|
|                                      | Dupilumab 300 mg qw (n=156) | Dupilumab 300 mg q4w (n=157) | Placebo (n=158) | Placebo (n=107) |
| Dupilumab 300 mg qw (n=148)          | 7 (1.1%)           | 2 (1.3%)               | 1.14 mL/200 mg q2w   | Placebo (n=313) |
| Dupilumab 200 mg q2w (n=150)         | 0 (0%)             | 2 (1.4%)               | 2 mL/300 mg q2w      | Placebo (n=631) |
| Placebo (n=321)                      | 2 (1.3%)           | 6 (1.9%)               | Combined             | Placebo (n=632) |
| Conjunctivitis†§                     | 1 (0.9%)           | 8 (1.5%)               | 15 (2.4%)            | Placebo (n=694) |
|                                      | 3 (1.3%)           | 12 (2.2%)              | 22 (3.4%)            | Placebo (n=1263) |
|                                      | 0 (0%)             | 0 (0%)                 | 1 (0.9%)             | Dupilumab 300 mg q2w (n=30) |

*These results are expressed in number of patients (percent).

**MEDRA PT.

†Cluster of preferred terms includes conjunctivitis of unspecified cause, allergic, bacterial and viral conjunctivitis, and atopic keratoconjunctivitis.

MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; qw, once weekly; q2w, every 2 weeks; q4W, every 4 weeks; q8w, every 8 weeks; q16w, every 16 weeks; TCS, topical corticosteroid.
Real-world data on dupilumab-associated conjunctivitis

Since the approval of dupilumab for the treatment of moderate-to-severe AD in the USA and Europe, several studies have been conducted in real-world clinical practice to compare with dupilumab clinical trials’ data.

A real-world retrospective study conducted in Spain evaluated dupilumab treatment outcomes in 27 patients with up to 52 weeks of follow-up. DAC was the most common AE observed, with 5 (16.6%) cases reported. All cases were transitory, and managed positively without dupilumab withdrawal. Another series of 70 patients from Spain reported six cases (8.6%) of mild DAC, all in patients with history of allergic conjunctivitis, without need of dupilumab withdrawal.

Another observational cohort study from the Netherlands with 95 patients verified eye symptoms in 59 (62%) patients. Among these 59 patients, 16 were referred to an ophthalmologist who made the diagnosis of DAC in 5 (56%) patients. Wang and colleagues analyzed medical records of 77 AD patients treated with standard dosing of dupilumab and observed the occurrence of six cases of DAC (7.79%), with all cases improving with appropriate ophthalmologic treatment. Another real-world retrospective study conducted in Italy included 109 adult patients, from 39 Italian centers. Conjunctivitis was the most frequently reported side effect, occurring in 12 of the 109 patients (11%). All events were mild and managed to succeed with topical medication. Also, two Canadian Caucasian hospitals conducted a real-world retrospective review that included 52 adult patients. In-line with the literature, the most common AE was conjunctivitis, which was reported in four patients (8%).

Compared with the results from clinical trials, the majority of these real-world studies have higher rates of DAC (up to 62%). However, when some of the patients were referred to an ophthalmologist, the diagnosis of conjunctivitis was confirmed in a lower percentage, suggesting that there may exist a slight overestimation of DAC by dermatologists. But, the awareness of DAC being a commonly reported AE in AD

### Table 3. Incidence of conjunctivitis in atopic dermatitis dupilumab trial in adolescents* – LIBERTY AD ADOL (R668-AD-1526), 20

| Patients with at least 1 event, n (%) | LIBERTY AD ADOL |
|-------------------------------------|-----------------|
|                                     | Dupilumab (combined) (n=165) | Dupilumab 300mg q4w (n=83) | Dupilumab 200/300mg q2w (n=82) | Placebo (n=85) |
| Conjunctivitis§§ | 17 (10.3%) | 9 (10.8%) | 8 (9.8%) | 4 (4.7%) |

*These results are expressed in number of patients (percent).
§ Cluster of preferred terms includes atopic keratoconjunctivitis, conjunctivitis, conjunctivitis allergic, conjunctivitis bacterial, and conjunctivitis viral.
MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; q2w, every 2 weeks; q4W, every 4 weeks.
patients receiving dupilumab may have influenced apparent increments in reported incidences of DAC over time.

Discussion

Most AD studies demonstrated that patients receiving dupilumab had higher incidence of DAC (8.6–22.1%) than placebo-treated patients (2.1–11.1%), except for the SOLO-CONTINUE study, with most cases being mild or moderate and resolving with topical eye therapies without need of suspending dupilumab treatment.\(^6,7,11–13\) In these trials, conjunctivitis was either patient reported or dermatologist assessed rather than ophthalmologist evaluated. However, in two real-world studies, the incidence of conjunctivitis in real life confirmed by ophthalmologists was higher, specifically 23–25%,\(^22–31\) This difference in conjunctivitis incidence may be due to the fact that DAC was reported by investigators (typically dermatologists or allergists) without any additional workup and ophthalmological referral, which might have led to an underestimation of this AE. In contrast, patients with other atopic comorbidities, such as asthma, chronic rhinosinusitis with nasal polyposis, and EoE, had identical and low incidence rates of conjunctivitis in both treatment groups (0–1.5% for dupilumab versus 0–3.3% for placebo).\(^14–17\)

Several factors may be responsible for the increased incidence of DAC, either AD related or dupilumab treatment related. Ocular disorders occur more frequently in AD patients. Additionally, patients with greater baseline AD severity, high levels of TARC and IgE, low serum levels of dupilumab, or a previous history of conjunctivitis had more susceptibility to new conjunctivitis.\(^21,34\) Baseline AD severity and previous conjunctivitis history are presumably independent risk factors for DAC regardless of therapy (dupilumab or placebo), provided that the frequency rises with baseline gravity and previous history in both treatment groups.\(^21\) The CAFÉ study had the highest level of AD severity at baseline, and the greatest rates of previous conjunctivitis history and new conjunctivitis events among all AD trials. An increased awareness of conjunctivitis events after reports of several studies may be the reason for these increments. Treister and colleagues\(^34\) demonstrated that the mean time from treatment initiation to the occurrence of conjunctivitis was 15.8 weeks; however, four patients developed conjunctivitis after 20 weeks, implying that the 16-week end point may have missed cases that occurred posteriorly. However, DAC incidence in the SOLO-CONTINUE study was the lowest, despite patients who achieved a good response to dupilumab in both SOLO studies being re-randomized to maintain dupilumab treatment or placebo for another 36 weeks in this trial.

Increased levels of some biomarkers, namely TARC, IgE, and eosinophils, are associated with higher AD severity.\(^6,8,31\) Therefore, it is not surprising that conjunctivitis was more frequent in patients with more severe AD at baseline and augmented biomarker levels. Also, in patients with both AD and ophthalmic complications, increased levels of IgE were observed.\(^8,35\) Dupilumab efficacy in AD (IGA 0/1; EASI-75) apparently was associated with lesser conjunctivitis rates than in the monotherapy group. In contrast, this pattern was incongruous in both CHRONOS and CAFÉ studies. As IGA 0/1 and EASI-75 were achieved by fewer patients with baseline severe AD and higher rates of comorbidities and AD biomarker levels are associated with higher disease severity, these risk factors may be interconnected.\(^21\)

Serum concentrations of dupilumab seem to have an inverse relationship with conjunctivitis events, implying that local undertreatment may play a role.\(^2,6\)

The exact pathogenesis of DAC as well as the connection between its diverse pathogenetic mechanisms is presently unknown. Compared with the overall population, prevalence of ocular comorbidities is higher among AD patients. Therefore, pre-existing ophthalmic conditions and a specific interaction between dupilumab and AD may be possibly accountable for this higher rate among dupilumab-treated patients with AD, especially as conjunctivitis events were not increased in other type 2 diseases with dupilumab, suggesting a particular mechanism connected to AD, and not an intrinsic effect of dupilumab.\(^2,15,21\)

AD is associated with barrier dysfunction of ocular surface epithelia, including defects in keratinocyte terminal differentiation, keratinocyte lipid production, and tight junctions, leading to augmented transepidermal water loss.\(^36–40\) Barrier impairment is equally detected in the altered mucosal tissues of other type 2 conditions; however, ocular disease is more frequent in AD.\(^21\) The difference in conjunctivitis incidence rates between trials of AD and other type 2 disorders could be in part explained by the presence of distinct barrier anomalies of the conjunctival tissues in AD when compared with the other type 2 diseases.\(^21\)

Various pathogenetic hypotheses have been suggested including: (i) blockage of IL-4 and IL-13 signaling pathways leading to higher activity of ligands, such as OX40L; (ii) increased Demodex mites; (iii) eosinophilia, which play a role in the occurrence of allergic eye conditions; (iv) reduced IL-13-related mucus production; (v) disruption of an immune-mediated response of conjunctival associated lymphoid tissue; and (vi) focal scarcity of conjunctival goblet cells.\(^21,34,39–41\) It is possible that multiple mechanisms may play a role, interacting at the same time. Also, the occurrence of DAC in patients with AD and those with other type 2 disorders may be affected by distinct mechanisms. Further elucidation is necessary to better understand the underlying mechanism of the ocular and periorificial adverse effects and describe the modifications occurring in the eye at molecular, cellular, and inflammatory levels during these incidents, as well as, throughout and after resolution.

Recently, two types of DAC were observed by ophthalmologists: a mild nonspecific conjunctivitis and keratitis with dry eyes and a more specific dupilumab-induced follicular conjunctivitis and limbitis; most cases were mild or moderate, and the
majority did not have any history of conjunctivitis.\textsuperscript{32,33} In the absence of ophthalmologic or microbiologic evaluation of conjunctivitis in all AD trials, it was neither feasible to recognize cases that were concrete or pathognomonic for dupilumab nor to corroborate whether they were infectious, allergic, or idiopathic.\textsuperscript{21} Investigators did not collect data on specific clinical characteristics of conjunctivitis, which makes it difficult to compare events between dupilumab and placebo. Additional investigation of the clinical features of DAC is necessary. Currently, there is no standard treatment to prevent and manage DAC. Eye drops of corticosteroids, antibiotics, and antihistamines or mast cell stabilizers were the most frequent therapies in these trials.\textsuperscript{21} Several successful therapeutic approaches used for treatment of DAC without discontinuation of dupilumab were reported and included TCS preparations (e.g. fluorometholone, dexamethasone, hydrocortisone), topical tacrolimus, cyclosporin eye drops, antibiotic plus TCS combination therapies, hyaluronic acid eye drops, and artificial tears.\textsuperscript{32,33,42,43} There is a risk of developing glaucoma or cataracts with long-term treatment with topical TCS; therefore, drugs with low penetration into the anterior chamber of the eye, such as fluorometholone, should be preferred. Another therapeutic option is ophthalmic preparations of calcineurin inhibitors, which seem to be a sensible alternative treatment for long term. Additionally, severe conjunctivitis can be treated with eye drops containing cyclosporine, which appear to be an appropriate option.\textsuperscript{44} Ocular irritation, a burning sensation, and local pain on application are possible side effects.\textsuperscript{44} Both tacrolimus and cyclosporine eye drops constitute off-label use agents. An ophthalmologist should evaluate patients with eye symptoms in order to properly diagnose DAC and exclude other forms of conjunctivitis, namely bacterial or viral. It would be of interest to add an ophthalmologist to the patient-management team and perform a systematic ophthalmological referral before dupilumab treatment. Maudinet and colleagues\textsuperscript{32} reported a 15% decrease in DAC incidence after initiation of standard ophthalmological assessment before dupilumab. Of note, with the use of hydroxychloroquine in autoimmune dermatoses, dermatologists recommend annual eye examinations due to the risk of hydroxychloroquine retinopathy. Patients with AD receiving dupilumab have a comparable risk of ocular complications; thereby, a recommendation for routine eye examinations should be acknowledged.

**Conclusion**

Following the approval of dupilumab in the USA and Europe, the proportion of patients treated with this drug will increase in the near future. Therefore, it is extremely important to assess the safety profile of dupilumab and manage its AEs. DAC incidence is higher in AD, and most cases are mild to moderate and have good response to topical treatment with a rapid clinical response, while patients maintain dupilumab. Given AD is a chronic disease, and dupilumab may be used in the long-term, therapeutic approaches for conjunctivitis should include agents with a good safety profile that can be administered long term. Further studies are necessary to characterize clinical phenotypes of DAC and understand its etiology so that strategies for prevention and collaborative care can be created.
Conjunctivitis associated with dupilumab

Ferreira F, Torres T. Drugs in Context 2020; 9: 2020-2-3.

References

1. Hanifin JM, Reed ML. A population-based survey of eczema prevalence in the United States. *Dermatitis*. 2007;18(2):82–91. http://doi.org/10.2310/6620.2007.06034
2. Ferreira S, Torres T. Dupilumab for the treatment of atopic dermatitis. *Acta Dermosifiliogr.* 2018;109(3):230–240. http://doi.org/10.1016/j.ad.2017.10.012
3. Chen JJ, Applebaum DS, Sun GS, et al. Atopic keratoconjunctivitis: a review. *J Am Acad Dermatol*. 2014;70:569–575. http://doi.org/10.1016/j.jaad.2013.10.036
4. Thysen JP, Toft PB, Halling-Overgaard AS, et al. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. *J Am Acad Dermatol*. 2017;77:280–286. http://doi.org/10.1016/j.jaad.2017.03.003
5. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatol Venereol*. 2018;32(6):850–878. http://doi.org/10.1111/jdv.14888
6. Simpson EL, Bieber T, Guttmann-Yassky E, et al. SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375(24):2335–2348. http://doi.org/10.1056/NEJMoa1610020
7. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet*. 2017;389(10086):2287–2303. http://doi.org/10.1016/S0140-6736(17)31191-1
8. Bielory L. Epidemiology of allergic conjunctivitis. *Immunol Allergy Clin N Am*. 2010;30:323–336. https://doi.org/10.1016/j.iac.2010.06.004
9. Thysen JP, Toft PB, Halling-Overgaard AS, et al. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. *J Am Acad Dermatol*. 2017;77:280–286. http://doi.org/10.1016/j.jaad.2017.03.003
10. Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. *Curr Opin Allergy Clin Immunol*. 2011;11:471–476. http://doi.org/10.1097/ACI.0b013e32834a9676
11. Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo controlled, dose-ranging phase 2b trial. *Lancet*. 2016;387:40–52. http://doi.org/10.1016/S0140-6736(15)00388-8
12. Worm M, Simpson EL, Thaçi D, et al. The effect of dose regimen adjustment on clinical response and safety of dupilumab in patients with atopic dermatitis (LIBERTY AD SOLO CONTINUE). Presented at the 37th Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI); Munich, Germany, 26–30 May, 2018.
13. de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). *Br J Dermatol*. 2018;178:1083–1101. http://doi.org/10.1111/bjd.16156
14. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet*. 2016;388:31–44. http://doi.org/10.1016/S0140-6736(16)30307-5
15. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med*. 2018;379(26):2335–2345. http://doi.org/10.1056/NEJMoa1804093
16. Rabe KF, Nair P, Brusselle G, et al. Dupilumab in patients with corticosteroid-dependent severe asthma: efficacy and safety results from the randomized, double-blind, placebo-controlled phase 3 LIBERTY ASTHMA VENTURE study. *Am J Respir Crit Care Med*. 2018;197:A7712. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A7712
17. Castro M, Corren J, Pavord I, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med*. 2018;379:2486–2496. http://doi.org/10.1056/NEJMoa1804092
18. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. *JAMA*. 2016;315:469–479. http://doi.org/10.1001/jama.2015.19330
19. Hirano I, Dellon ES, Hamilton JD, et al. Dupilumab efficacy and safety in adult patients with active eosinophilic oesophagitis: a randomized double-blind placebo-controlled phase 2 trial. *United European Gastroenterol J*. 2017;5:1138–1150. http://doi.org/10.1053/j.gastro.2019.09.042
20. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;156(1):44–56. http://doi.org/10.1001/jamadermatol.2019.3336

21. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis associated with dupilumab in clinical trials. Br J Dermatol. 2019;181(3):459–473. http://doi.org/10.1111/bjd.17869

22. Ruiz-Villaverde R, Dominguez-Cruz J, Armario-Hita JC, et al. Dupilumab: short-term effectiveness and safety in real clinical practice – a retrospective multicentric study. J Eur Acad Dermatol Venereol. 2019;33(1):e21–e22. http://doi.org/10.1111/jdv.15118

23. Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol. 2019;181(5):1072–1074. http://doi.org/10.1111/bjd.18041

24. Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143–151. http://doi.org/10.1016/j.jaad.2019.02.053

25. de Wijs LEM, Bosma AL, Erler NS, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2020;182(2):418–426. http://doi.org/10.1111/bjd.17189

26. Wang C, Kraus CN, Patel KG, et al. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients’ records. Int J Dermatol. 2020;59(2):253–256. http://doi.org/10.1111/ijd.14573

27. Fargnoli MC, Esposito M, Ferrucci S, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2019 Oct 28:1–7. http://doi.org/10.1080/09546634.2019.1682503. [Epub ahead of print]

28. Jo CE, Georgakopoulos JR, Ladda M, et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: A retrospective cohort study. J Am Acad Dermatol. 2020 Feb 16. http://doi.org/10.1016/j.jaad.2020.02.029. [Epub ahead of print]

29. Ribero S, Giura MT, Viola R, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2020;181(5):1248–1249. http://doi.org/10.1111/bjd.17538

30. Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208–1211. http://doi.org/10.1001/jamadermatol.2018.2690

31. Liberman P, Shifera AS, Berkenstock M. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Invest Allergol Clin Immunol. 2020 Jan 14. http://doi.org/10.18176/jiaci.0481. [Epub ahead of print]

32. Maudinet A, Law-Koune S, Duret C, et al. Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther. 2019;8(3):485–490. http://doi.org/10.1016/j.s40123-019-0091-9

33. Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180(5):1248–1249. http://doi.org/10.1111/bjd.17538

34. Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208–1211. http://doi.org/10.1001/jamadermatol.2018.2690

35. Utine CA, Stern M, Akpek EK. Immunopathological features of severe chronic atopic keratoconjunctivitis and effects of topical cyclosporine treatment. Ocul Immunol Inflamm. 2019;27(7):1184–1193. http://doi.org/10.1080/09273948.2018.1511811

36. Wollenberg A, Ariens L, Thurau S, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab. Br J Dermatol. 2019;181(3):1072–1074. http://doi.org/10.1111/bjd.18041

37. Yokoi K, Yokoi N, Kinoshita S. Impairment of ocular surface epithelium barrier function in patients with atopic dermatitis. Br J Dermatol. 1998;139(1);82–87. http://doi.org/10.1111/j.1365-2133.1998.tb18889.x

38. Ghosh A, Wu C, Takahashi K, et al. Corneal innervation and atopic keratoconjunctivitis: a case report. Allergy Asthma Proc. 2013;34(3):239–243. http://doi.org/10.2500/aap.2013.34.3612

39. Utine CA, Stern M, Akpek EK. Immunopathological features of severe chronic atopic keratoconjunctivitis and effects of topical cyclosporine treatment. Ocul Immunol Inflamm. 2019;27(7):1184–1193. http://doi.org/10.1080/09273948.2018.1511811

40. Wollenberg A, Ariens L, Thurau S, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab. Br J Dermatol. 2019;180(5):1248–1249. http://doi.org/10.1111/bjd.17538

41. Fargnoli MC, Esposito M, Ferrucci S, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2019 Oct 28:1–7. http://doi.org/10.1080/09546634.2019.1682503. [Epub ahead of print]

42. Liberman P, Shifera AS, Berkenstock M. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Invest Allergol Clin Immunol. 2020 January 14. http://doi.org/10.18176/jiaci.0481. [Epub ahead of print]

43. Liberman P, Shifera AS, Berkenstock M. Dupilumab-associated conjunctivitis in patients with atopic dermatitis. Cornea. 2020 Jan 24. http://doi.org/10.1097/ICO.0000000000002262. [Epub ahead of print]

44. Liberman P, Shifera AS, Berkenstock M. Dupilumab-associated conjunctivitis in patients with atopic dermatitis. Cornea. 2020 January 24. http://doi.org/10.1097/ICO.0000000000002262. [Epub ahead of print]

45. Utine CA, Stern M, Akpek EK. Immunopathological features of severe chronic atopic keratoconjunctivitis and effects of topical cyclosporine treatment. Ocul Immunol Inflamm. 2019;27(7):1184–1193. http://doi.org/10.1080/09273948.2018.1511811